IL142231A0 - Mutant cholera holotoxin as an adjuvant - Google Patents
Mutant cholera holotoxin as an adjuvantInfo
- Publication number
- IL142231A0 IL142231A0 IL14223199A IL14223199A IL142231A0 IL 142231 A0 IL142231 A0 IL 142231A0 IL 14223199 A IL14223199 A IL 14223199A IL 14223199 A IL14223199 A IL 14223199A IL 142231 A0 IL142231 A0 IL 142231A0
- Authority
- IL
- Israel
- Prior art keywords
- adjuvant
- amino acid
- cholera holotoxin
- mutant cholera
- subunit
- Prior art date
Links
- 206010008631 Cholera Diseases 0.000 title abstract 4
- 229930186900 holotoxin Natural products 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 241000233866 Fungi Species 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10243098P | 1998-09-30 | 1998-09-30 | |
PCT/US1999/022520 WO2000018434A1 (en) | 1998-09-30 | 1999-09-30 | Mutant cholera holotoxin as an adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
IL142231A0 true IL142231A0 (en) | 2002-03-10 |
Family
ID=22289805
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14223199A IL142231A0 (en) | 1998-09-30 | 1999-09-30 | Mutant cholera holotoxin as an adjuvant |
IL142231A IL142231A (en) | 1998-09-30 | 2001-03-25 | Antigenic composition comprising a selected antigen and a mutant cholera holotoxin as an adjuvant, a method of producing such mutant cholera holotoxin and use thereof in an antigenic composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL142231A IL142231A (en) | 1998-09-30 | 2001-03-25 | Antigenic composition comprising a selected antigen and a mutant cholera holotoxin as an adjuvant, a method of producing such mutant cholera holotoxin and use thereof in an antigenic composition |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1117435B1 (xx) |
JP (1) | JP4673974B2 (xx) |
KR (1) | KR100659803B1 (xx) |
CN (1) | CN1197618C (xx) |
AT (1) | ATE378066T1 (xx) |
AU (1) | AU770333B2 (xx) |
BR (1) | BR9914160A (xx) |
CA (1) | CA2344740C (xx) |
CY (1) | CY1107276T1 (xx) |
DE (1) | DE69937571T2 (xx) |
DK (1) | DK1117435T3 (xx) |
ES (1) | ES2293735T3 (xx) |
IL (2) | IL142231A0 (xx) |
MX (1) | MXPA01003228A (xx) |
PT (1) | PT1117435E (xx) |
WO (1) | WO2000018434A1 (xx) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1995009649A1 (en) | 1993-10-05 | 1995-04-13 | Medeva Holdings B.V. | Vaccine compositions |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
KR100877019B1 (ko) | 2000-06-23 | 2009-01-07 | 와이어쓰 홀딩스 코포레이션 | 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립 |
JP4445200B2 (ja) | 2000-12-28 | 2010-04-07 | ワイス エルエルシー | $i(streptococcuspneumoniae)由来の組換え保護タンパク質 |
CN1636062A (zh) | 2001-04-16 | 2005-07-06 | 惠氏控股公司 | 编码多肽抗原的新肺炎链球菌可读框及其应用 |
IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
DE60234695D1 (de) | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
DE60236596D1 (de) | 2001-07-27 | 2010-07-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
WO2003078453A1 (en) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
CA2519511A1 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
WO2004094596A2 (en) * | 2003-04-16 | 2004-11-04 | Wyeth Holdings Corporation | Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
WO2005020902A2 (en) | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
TWI379839B (en) | 2003-12-17 | 2012-12-21 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and methods of producing same |
WO2005058940A2 (en) | 2003-12-17 | 2005-06-30 | Wyeth | Immunogenic peptide carrier conjugates and methods of producing same |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
EP1749024A2 (en) | 2004-05-21 | 2007-02-07 | Wyeth a Corporation of the State of Delaware | Altered fibronectin-binding protein of staphylococcus aureus |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
EP1796719B1 (en) | 2004-10-06 | 2014-12-03 | MedImmune, LLC | Refrigerator-temperature stable influenza vaccine compositions |
EP2298341A3 (en) | 2004-10-21 | 2011-07-13 | Wyeth LLC | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN113198012A (zh) | 2005-04-08 | 2021-08-03 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
WO2008109410A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
DK2356135T3 (en) | 2008-11-05 | 2017-12-04 | Wyeth Llc | IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE |
CA2743306A1 (en) | 2008-11-12 | 2010-05-20 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
US9260691B2 (en) | 2010-05-19 | 2016-02-16 | Bioproperties Pty Ltd | Methods relating to an attenuated mycoplasma |
PT3170508T (pt) | 2010-06-04 | 2020-01-16 | Wyeth Llc | Formulações de vacinas |
PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
RU2665841C2 (ru) | 2012-03-09 | 2018-09-04 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их применения |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP2875041A2 (en) | 2012-07-19 | 2015-05-27 | Zoetis LLC | Bovine influenza c virus compositions |
WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
PL2885007T3 (pl) | 2012-08-16 | 2019-02-28 | Pfizer Inc. | Sposoby glikokoniugacji i kompozycje |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
US20160008449A1 (en) | 2013-03-15 | 2016-01-14 | Zoetis Services Llc | CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE |
KR20180099912A (ko) | 2013-09-08 | 2018-09-05 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
PT3096783T (pt) | 2014-01-21 | 2021-08-16 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
RU2688831C2 (ru) | 2014-01-21 | 2019-05-22 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
ES2933623T3 (es) | 2015-08-14 | 2023-02-10 | Zoetis Services Llc | Composiciones de Mycoplasma Bovis |
WO2017123201A1 (en) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
EP4327876A2 (en) | 2017-06-23 | 2024-02-28 | Affinivax, Inc. | Immunogenic compositions |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CN114728050A (zh) | 2019-07-31 | 2022-07-08 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法 |
US20230233652A1 (en) | 2020-04-16 | 2023-07-27 | Par'immune Sas | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
JP2023542036A (ja) | 2020-09-17 | 2023-10-04 | ネオヴァクス | IgE介在性炎症性障害を治療するためのIgEフラグメントを含む免疫原性産物 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
AU6505796A (en) * | 1995-07-26 | 1997-02-26 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1998045324A1 (en) * | 1997-04-04 | 1998-10-15 | The Uab Research Foundation | Use of cholera toxin mutants as mucosal adjuvants |
-
1999
- 1999-09-30 PT PT99951639T patent/PT1117435E/pt unknown
- 1999-09-30 EP EP99951639A patent/EP1117435B1/en not_active Expired - Lifetime
- 1999-09-30 KR KR1020017003968A patent/KR100659803B1/ko not_active IP Right Cessation
- 1999-09-30 DK DK99951639T patent/DK1117435T3/da active
- 1999-09-30 AT AT99951639T patent/ATE378066T1/de not_active IP Right Cessation
- 1999-09-30 BR BR9914160-4A patent/BR9914160A/pt not_active Application Discontinuation
- 1999-09-30 CA CA2344740A patent/CA2344740C/en not_active Expired - Fee Related
- 1999-09-30 CN CNB998115576A patent/CN1197618C/zh not_active Expired - Fee Related
- 1999-09-30 WO PCT/US1999/022520 patent/WO2000018434A1/en active IP Right Grant
- 1999-09-30 ES ES99951639T patent/ES2293735T3/es not_active Expired - Lifetime
- 1999-09-30 AU AU64039/99A patent/AU770333B2/en not_active Ceased
- 1999-09-30 DE DE69937571T patent/DE69937571T2/de not_active Expired - Lifetime
- 1999-09-30 IL IL14223199A patent/IL142231A0/xx unknown
- 1999-09-30 JP JP2000571951A patent/JP4673974B2/ja not_active Expired - Fee Related
- 1999-09-30 MX MXPA01003228A patent/MXPA01003228A/es not_active IP Right Cessation
-
2001
- 2001-03-25 IL IL142231A patent/IL142231A/en not_active IP Right Cessation
-
2008
- 2008-02-01 CY CY20081100125T patent/CY1107276T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1197618C (zh) | 2005-04-20 |
MXPA01003228A (es) | 2003-06-24 |
KR20010085859A (ko) | 2001-09-07 |
JP4673974B2 (ja) | 2011-04-20 |
DE69937571T2 (de) | 2008-09-04 |
ATE378066T1 (de) | 2007-11-15 |
ES2293735T3 (es) | 2008-03-16 |
DK1117435T3 (da) | 2008-03-17 |
EP1117435A1 (en) | 2001-07-25 |
BR9914160A (pt) | 2001-06-26 |
CA2344740A1 (en) | 2000-04-06 |
CA2344740C (en) | 2011-11-22 |
EP1117435B1 (en) | 2007-11-14 |
CY1107276T1 (el) | 2012-11-21 |
PT1117435E (pt) | 2008-02-21 |
JP2002525093A (ja) | 2002-08-13 |
WO2000018434A1 (en) | 2000-04-06 |
KR100659803B1 (ko) | 2006-12-19 |
IL142231A (en) | 2010-05-31 |
AU770333B2 (en) | 2004-02-19 |
AU6403999A (en) | 2000-04-17 |
CN1320043A (zh) | 2001-10-31 |
DE69937571D1 (de) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL142231A0 (en) | Mutant cholera holotoxin as an adjuvant | |
IL159210A0 (en) | Mutant forms of cholera holotoxin as an adjuvant | |
WO2002098369A3 (en) | Mutant forms of cholera holotoxin as an adjuvant | |
AU2875700A (en) | Microemulsions with adsorbed macromoelecules and microparticles | |
WO2004083251A3 (en) | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein | |
BR9906927A (pt) | Proteìnas de neisseria meningitidis | |
HK1121382A1 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines | |
DE60044005D1 (de) | 85 kDa Antigen von Neisseria | |
TW266228B (xx) | ||
PL351894A1 (en) | Novel compositions | |
CA2190344A1 (en) | Quillaja saponin adjuvant and vaccine formulation containing same | |
EP1467771A4 (en) | MYCOBACTERIAL VACCINE | |
GEP20053446B (en) | Adjuvant Combination Formulations | |
PT1575483E (pt) | Bactérias gram negativas atenuadas | |
WO2000050073A3 (en) | Caulobacter lps immunoadjuvant | |
PT757556E (pt) | Bacterina borrelia burgdorferi | |
FI934331A0 (fi) | Nya proteaser | |
DK1350796T3 (da) | Attenuerede gramnegative bakterier | |
DE60232413D1 (en) | Ltb4 als adjuvans für impfstoffe | |
GB9500788D0 (en) | Vaccine compositions | |
RU2227043C2 (ru) | Антигены neisseria meningitidis и композиции | |
GR20010100450A (el) | Η μελανινη ως ανοσοενισχυτικο |